New antibody drug tested in patients with advanced stomach and gut cancers
NCT ID NCT05639153
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called DR30303 in 13 people with advanced digestive system cancers that had stopped responding to standard treatments. The drug is a lab-made antibody designed to target a protein called CLDN18.2 found on some cancer cells. The main goals were to check safety, find the best dose, and see if the drug could shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sir Run Run Shaw Hospital，Zhejiang University School of Medicine
Hanzhou, Zhejiang, 311100, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can a new antibody help the immune system fight advanced cancers?